Showing 741-750 of 10588 results for "".
Alloimmune Neutropenia of the Fetus and Newborn
https://reachmd.com/programs/cme/alloimmune-neutropenia-of-the-fetus-and-newborn/13910/NAIN is rare and potentially life-threatening. What clues can increase your awareness and help you modify the clinical course of this disease?Clinical Neuroinflammatory Mimics of Multiple Sclerosis
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/clinical-neuroinflammatory-mimics-of-multiple-sclerosis/54599/NMOSD, MOGAD, and MS have overlapping clinical presentations but are distinct inflammatory CNS diseases, each with their own established diagnostic criteria.Achieving Success in IgAN & FSGS
https://reachmd.com/programs/cme/achieving-success-in-igan-fsgs/14677/Review underlying mechanisms of glomerulonephritis and sclerosis in patients with IgAN and FSGS and find out how emerging data may improve outcomes.New Product Evaluation Basics in Aesthetic Practices
https://reachmd.com/topics/injectables/new-product-evaluation-basics-in-aesthetic-practices/35166/Choice of methodology can lead to widely different conclusions: A single-center experience.Relapse Management in Multiple Sclerosis: Corticosteroids Remain the Linchpin of Therapies
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/relapse-management-in-multiple-sclerosis-corticosteroids-remain-the-linchpin-of-therapies/32084/Several modalities are available for the treatment of multiple sclerosis relapse, including corticosteroids, intravenous immunoglobulins, and therapeutic apheresis.Insights and Updates: New Data on Next-Generation Retinal Treatments
https://reachmd.com/programs/cme/Insights-and-Updates-New-Data-on-Next-Generation-Retinal-Treatments/36107/Join our faculty as they discuss the latest clinical and real-world data surrounding faricimab, aflibercept 8 mg, and the PDS with ranibizumab.Hyperpigmentation in Darker Skin Types: A Review of Current Treatments
https://reachmd.com/programs/practical-dermatology/hyperpigmentation-in-darker-skin-types-a-review-of-current-treatments/24217/Pigmentary disorders are a leading concern for patients and consumers worldwide.Treatment of OAB and the Managed Care Professional: Balancing the Double-Edged Sword
https://reachmd.com/programs/cme/treatment-of-oab-and-the-managed-care-professional-balancing-the-double-edged-sword/15362/Are you prepared to actively engage with your patients about their overactive bladder?Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
https://reachmd.com/programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025/Exploring CETP inhibition as the next breakthrough in lipid lowering, cardiologists highlight mechanisms, trials, and its role as a future CV therapy.FSGS in Practice: Patient-Centered Decision-Making
https://reachmd.com/programs/cme/fsgs-in-practice-patient-centered-decision-making/35713/Join our expert nephrology faculty and learn about practical strategies for improving your diagnostic skills and treatment selection in FSGS.